Halaven

Halaven

Manufacturer:

Eisai

Distributor:

Zuellig
/
HI-Eisai
Concise Prescribing Info
Contents
Eribulin mesilate
Indications/Uses
Locally advanced or metastatic breast cancer who have progressed after at least 1 chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline & a taxane in either adjuvant or metastatic setting unless patients were not suitable for these treatments. Soft tissue sarcoma.
Dosage/Direction for Use
1.4 mg/m2 IV over 2-5 min on days 1 & 8 of every 21-day cycle. Patient w/ mild hepatic impairment (Child-Pugh A) 1.1 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle. Moderate hepatic impairment (Child-Pugh B) 0.7 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle.
Contraindications
Special Precautions
Monitor complete blood count prior to each dose. Higher incidence of grade 4 & febrile neutropenia in patients w/ ALT or AST >3 x ULN or bilirubin >1.5 x ULN. Peripheral neuropathy. Avoid in patients w/ congenital long QT syndrome & perform ECG to patients w/ CHF, bradyarrhythmias, concomitant use of drugs that prolong QT interval including class Ia & III antiarrhythmics & electrolyte abnormalities. Hypokalemia & hypomagnesemia should be corrected prior to initiation & monitored periodically during therapy. Concomitant use w/ anti-HER2 therapy. Contains small amounts of ethanol (alcohol) <100 mg/dose. Possibility of irreversible infertility in male patients. May affect ability to drive or operate machinery. Pregnancy.
Adverse Reactions
Bone marrow suppression manifested as neutropenia, leukopenia, anemia, thrombocytopenia w/ associated infections. New onset or worsening of preexisting peripheral neuropathy. GI toxicities manifested as anorexia, nausea, vomiting, diarrhea, constipation & stomatitis. Fatigue, alopecia, increased liver enzymes, sepsis & musculoskeletal pain syndrome.
Drug Interactions
Drugs w/ narrow therapeutic window & eliminated via CYP3A4-mediated metabolism (eg, alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus).
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XX41 - eribulin ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Halaven soln for inj 500 mcg/mL
Packing/Price
2 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in